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Introduction
Ameloblastoma (AM) is a rare benign neoplasm of the 
jawbones and surrounding tissues that originate from the 
epithelium of the tooth-forming apparatus.1 Although 
benign, it is characterised by locally aggressive behaviour 
and consequent high rate of recurrences.1,2 The risk of dis-
ease recurrence can be minimised by removing the tumour 
with wide margins of surrounding bone tissue (resection 
surgery), at the cost of permanent functional and cosmetic 
consequences.1 Incomplete removal of the tumour can be 
life threatening due to disease progression into vital struc-
tures of the head and neck, including the brain.2
Currently, therapeutic agents are not widely used to 
treat the tumour, with some recent exceptions.3 Very little 
is known about the mechanisms controlling AM growth, 
its interactions with the surrounding cellular and extracel-
lular microenvironment and the associated extensive bone 
resorption. To this end, a co-culture scaffold has been 
developed to model the growth of the tumour, which in the 
future could be used to test tailored therapeutic agents on 
AM cells.4 A recent paper revealed a potential molecular 
background to the location of AM in jawbones and thera-
peutic targets.5
Bone formation in vivo is well understood, with the 
osteoprotegerin (OPG)/receptor activator of nuclear factor 
kappa-B ligand (RANKL) pathway and bone morphogenic 
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proteins (BMPs) central to it.6 Some recent molecular 
investigations and reviews support the osteoclast-upregu-
lating theory that RANKL is responsible for activating 
osteoclasts and thus triggering bone resorption in both 
healthy and diseased tissues.6,7 OPG is a decoy receptor for 
the RANKL, and therefore, an increase in OPG decreases 
RANKL and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) activity and corresponding bone 
resorption.8
The OPG/RANKL pathway has clearly been shown as 
fundamental in bone remodelling in oral squamous cell 
carcinoma (OSCC) cases.9 Genes involved in bone turno-
ver have also been previously implicated in AM, with 
studies showing increasing or variable levels of RANKL,10 
BMPs11 and OPG.12 Therefore, it was decided to further 
investigate the relationship between AM and genes 
involved in bone regulation.
Tissue engineering has recently been used for tumour 
modelling to great effect, both in basic tumour cell research 
and for testing therapeutic agents.13–15 Constructs created 
using tissue engineering techniques can be tumour site spe-
cific, relatively cheap, used for high-throughput analyses 
and both refine and reduce the use of animals in research.
This article details a process by which an organotypic 
co-culture model of AM has been created using tissue 
engineering techniques. This model was thus used to per-
form gene expression experiments to further detail the 
pathways involved in bone turnover in AM tumours, as 
well as to look at AM growth on a cellular level in these 
models. This model can further be used for in vitro experi-
ments to detail invasion processes, cell-to-cell behaviour 
and even screening for therapeutic compounds.
Aim
The aim of this study was to incorporate AM tumour cells 
into an in vitro, bone-like model and assess the effect of a 
co-culture environment on AM-1 cells and their expres-
sion of genes involved in bone turnover. Furthermore, the 




Plastic compressed16 collagen type I (First Link, UK) gels 
formed the basis of the three-dimensional (3D) cellular-
ised models. Bone-like scaffolds were constructed from 
human osteosarcoma (HOS) cell line (ATCC, UK), which 
were added to neutralised collagen gels at 300,000 cells/
mL. Bio-Oss granules (Geistlich, Switzerland) were added 
to the collagen prior to compression. The Bio-Oss granules 
are made from decellularised bone and thus provide addi-
tional mineral and mechanical cues. The final percentage 
of these two components in the constructs was approxi-
mately 70% collagen and 30% Bio-Oss granules. The 
bone-like constructs were incubated in mineralising media 
made from Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen, UK) with 10 nM beta-glycerophosphate, 50 µM 
ascorbate-2-phosphate and 10 nM dexamethasone (all 
from Sigma–Aldrich, UK) for up to 14 days.
Analysis of scaffold mineralisation
Scaffold mineral content was measured using Von Kossa 
histological staining of formalin-fixed paraffin-embedded 
samples. Briefly, the samples on slides were brought to 
water, the sections incubated in 0.5% aqueous silver nitrate 
under ultraviolet (UV) light for 1 h, washed and fixed in 
5% sodium thiosulphate. Cell nuclei were counterstained 
with 1% neutral red solution.
An alkaline phosphatase (ALP) assay SensoLyte pNPP 
ALP kit (AnaSpec, USA) was used to quantify the production 
of ALP, which is indicative of mineralisation. The manufac-
turer’s protocol for ‘tissue extract preparation’ was followed.
AM-1 organotypic co-cultures
AM-1 cells17 were added to a separate collagen type I gel 
once the bone part of the model had been cultured for 
14 days. The two gels were placed next to each other and 
combined using an acellular collagen gel as a supporting 
‘glue’ layer as visualised in Figure 1, and a further applica-
tion of compression. The co-culture gels were incubated 
up to 14 days in keratinocyte serum-free medium (KSFM; 
Gibco, UK) for cell expansion and scaffold remodelling.
Cell staining
Live/Dead staining (Life Technologies, UK) with 2 µM 
Calcein AM as the ‘live’ cytoplasmic stain and 4 µM eth-
idium homodimer-1 as the nuclear ‘dead’ stain was used to 
Figure 1. Schematic diagram of the co-culture construct 
setup. The bone-like construct part was composed of Bio-
Oss granules (empty shapes) and HOS cells (black) within a 
collagen construct, whereas the AM-1 construct was made 
by incorporating AM-1 cells (grey) within a collagen gel. An 
acellular support gel was included in order to ensure the co-
culture construct joined together. The interface between the 
two constructs is also indicated.
Eriksson et al. 3
stain all cells in the constructs to ensure they remained 
alive throughout the culture period.
Cell behaviour and interactions in the scaffolds were 
analysed using immunofluorescence: bone cells were 
stained using a mouse anti-osteopontin primary antibody 
(1:500; Abcam, UK) and Alexa Fluor 488 (1:200; Life 
Technologies) secondary antibody on methanol-fixed 
and permeabilised co-cultures. All cell nuclei were 
stained using the ‘dead’ stain as above and viewed under 
a Bio-Rad confocal laser-scanning microscope (Bio-
Rad, UK).
Cell proliferation
Changes in intracellular adenosine triphosphate (ATP) 
levels in the co-culture constructs were used to indicate 
cell proliferation. For this, the CellTiter-Glo luminescent 
cell proliferation assay (Promega, USA) was used. This 
assay reagent was specifically developed to be used with 
3D cellularised models. The reagent was added in a 1:1 
ratio with KSFM to the constructs on a 96-well plate and 
incubated at room temperature for 30 min to allow for 
cell lysis and reagent stabilisation. The luminescence sig-
nal was then read using a BioTek FLx800 (BioTek, UK) 
plate reader.
Prior to cell seeding, 3 µM Transwell inserts (Corning, 
UK) were coated with 70 µL of collagen type I. The wells 
at the bottom were seeded with HOS cells in a monolayer. 
Foetal bovine serum (Gibco) was used as a chemoattract-
ant in half of the wells. AM-1 cells seeded on top of the 
collagen insert were allowed to migrate through for 72 h 
before cell counting.
Gene expression analysis
RNA was extracted from the collagen gels using a fibrous 
tissue RNeasy kit (Qiagen, UK), cDNA was synthesised 
using the high-capacity cDNA-to-RNA kit (Applied 
Biosystems, UK). Relative mRNA levels were quantified 
with quantitative real-time polymerase chain reaction 
(qRT-PCR) using TaqMan gene expression Master Mix 
and TaqMan gene expression assay primers for RANKL, 
OPG, tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) and NF-κB (all from Applied Biosystems). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA was used as an endogenous control. Values show-
ing a fold change in the mRNA levels compared to day 0 
‘no co-culture’ calibrator sample values were plotted.
Statistical analysis
Graphs were plotted and statistical analysis, analysis of 
variance (ANOVA) was carried out using GraphPad Prism 
6 (GraphPad, USA). The error bars on all graphs indicate 
the 95% confidence interval. N = 3 unless otherwise stated.
Results and discussions
The decellularised Bio-Oss bone particles provided the 
HOS-cellularised bone-like constructs with additional 
mineral, which is visible using Von Kossa staining from 
day 1 (Figure 2(a)). The cells within the constructs then 
produced more mineral, as is evident from the increased 
staining seen in the samples with increasing culture time 
(Figure 2(b) and (c)). Cellularised collagen gels without 
the added bone particles are slow to mineralise, with only 
cell nuclei present early on in culture (Figure 2(d)).
The addition of Bio-Oss bone particles provided the 
constructs with minerals, as well as a bone-like micro-
structure with pores and an improved bone-like mechani-
cal environment.18–20 As the final ratio of particles used 
was 70% collagen to 30% Bio-Oss, we were still able to 
examine the constructs using light and fluorescence 
microscopy to provide indications of cell health, migra-
tion, interactions and invasion.
ALP activity was used as a measure of bone formation 
and an indicator of the presence of osteoblasts in the single-
cell-type bone-like constructs to ensure an organotypic 
environment prior to the addition of AM-1 cells.
The levels of ALP increased in the constructs during 
the first week when measured using a quantitative 
protein-based assay (Figure 2(g)). This indicated the 
presence of active osteoblasts in the constructs. After the 
first week, the level of ALP plateaus gradually declines, 
which is due to cells in the constructs reaching conflu-
ence, hypoxia-caused cell death in parts of the construct 
or cells migrating deep inside these particles and thus not 
included in the analysis. Using gene expression data, we 
were able to show an increase in ALP mRNA levels in the 
constructs throughout the culture period of 14 days 
(Figure 2(f)).
Similar to another study on a comparable bone-like tis-
sue engineered construct, we found that bone cells are able 
to mineralise a plastic compressed collagen scaffold on 
their own in long-term culture.21 Our results show that cul-
tures go on to mineralise the construct by day 35 (Figure 
2(e)), which indicated there were viable, active osteoblasts 
present in the constructs. However, as this was the first 
step in a long co-culture model synthesis, the addition of 
bone mineral to the scaffolds was deemed a suitable step to 
accelerate the process.
Based on this data, subsequent experiments with the 
bone-like scaffold alone were limited to 14 days and the 
co-culture models were set up at this point.
Cells in the bone-like scaffold proliferate at a higher rate 
during the first week in culture, after which proliferation 
plateaus off (Figure 3(a)). This may be due to the cells 
reaching confluence earlier within the constructs, difficulty 
with reagent penetration to cells which may have migrated 
to within the Bio-Oss particles or cell death caused by 
nutrient deficiencies deeper inside the constructs.
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AM-1 cells within the collagen constructs have a slower 
initial proliferation rate, but adhere to an exponential rate 
of proliferation as expected (Figure 3(b)). Both cell types 
proliferate and survive within the co-culture constructs 
during the 14-day culture time. Cell survival was meas-
ured both quantitatively by measuring the intracellular 
ATP content (Figures 3(a) and 2(b)) and qualitatively using 
Live/Dead staining (Figure 3(c)–(f)). Both these assays 
showed that the cells were viable in the co-culture scaf-
folds and proliferating.
The interface between the two cellularised gels was 
examined using confocal microscopy. The white dotted 
line (Figure 4(a) and (b)) roughly indicates where the two 
different gels meet in the co-cultures, with the AM part 
above the line and the bone part below. In all gels exam-
ined, HOS cells were aligned in the direction of the gel 
edge day 7 (Figure 4(a)). Here, a cluster of AM-1 cells are 
visible close by. By day 14 (Figure 4(b)), AM-1 cells in 
some, but not all, samples had migrated through to the 
bone part of the scaffold; invasion in these gels was diffi-
cult to quantify.
Migration of AM-1 cells to the bone-like part of the 
construct was quantified using Transwell inserts (Figure 
4(c)). Approximately 10% of AM-1 cells seeded onto the 
top of a Transwell insert migrated through the collagen 
gel and porous membrane without chemoattractant 
(Figure 4(c)). There was no significant difference in AM-1 
cell numbers migrated through Transwell inserts towards 
a HOS monolayer with or without a chemoattractant. 
However, as very little migration was seen when HOS 
cells were omitted, there was a significant difference in 
AM-1 migration with and without HOS cells. These 
Figure 2. Mineralisation of single-cell-type bone-like collagen and Bio-Oss constructs. In (a)–(e), the mineral within the scaffolds 
was stained dark brown and cell nuclei were counterstained red. (a) HOS + Bio-Oss gel on day 1 stained for mineral using the Von 
Kossa histological stain, as expected with the addition of the bone particles. (b) Mineral in constructs appeared increased by day 7 in 
culture. (c) A further increase in staining is seen by day 14 in the HOS + Bio-Oss gels. (d) A HOS-only collagen gel is shown, where 
cell nuclei are clearly visible on day 7 of culture, but no staining for minerals present. (e) However, abundant Von Kossa staining 
for minerals in the construct is apparent by 35 days in culture, with the entire constructs appearing mineralised. (f) Expression 
of alkaline phosphatase mRNA levels in the constructs increases in the HOS + Bio-Oss constructs with increasing culture time, 
whereas a slower increase was seen in collagen-only HOS-cellularised constructs, indicating slower construct mineralisation. (g) 
Alkaline phosphatase activity levels as measured using a colorimetric, quantifiable assay showed a larger increase in the constructs 
with added Bio-Oss than in the collagen-only constructs. Scale bars from (a)–(e) = 50 µm. An asterisk (*) indicates statistically 
significant results, p < 0.05.
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Figure 3. Cell proliferation as measured using the CellTiter-Glo ATP assay during 14 days in co-culture scaffolds in (a) HOS cells 
and (b) AM-1 cells. Cell numbers were normalised to values obtained on day 0 of co-culture to show co-culture proliferation levels. 
An increase is seen in both cell types. The rate of proliferation appears to slow down in HOS cells after the first week in co-culture, 
and the subsequent differences are not statistically significant. (c)–(f) Composite images of typical Live (green)/Dead (red) staining 
of both cell types in the scaffolds (40× magnification). (c) HOS day 7. (d) Day 14. All HOS cells appear alive on day 7 of culture, 
and only a few dead cells were seen in the constructs on day 14, by which point the collagen models were approaching confluency. 
AM-1 cells exhibit a characteristic clustering behaviour, with the size of these clusters with increasing time in culture. (e) AM-1 cells 
in clusters on day 7. (f) AM-1 on day 14.
Figure 4. The interface region of the co-culture models and invasion as examined using immunocytochemistry and Transwell 
inserts. (a, b) The HOS cells were stained for the osteoblast marker OPN (green). Both HOS and AM-1 cells were counterstained 
with nuclear EthD1 (red). AM-1 cells (white arrows) were seen in clusters close to the interface). The white line indicates the two 
different constructs’ interface in the co-cultures. (a) In the first week of culture, HOS cells (lower half of the image) line up along the 
gel interface. (b) During the second week, the two cell types were seen in close proximity at the gel interface. (c) Quantification of 
cell migration to the other cell type through Transwell inserts. No significant differences were found in wells with or without added 
chemoattractant when AM-1 cell migration was measured. There is, however, a difference between wells where a HOS monolayer 
was used on the bottom of the inserts (first and second columns) and where no cells were used (third column; p < 0.05), indicating 
that AM-1 cell migration is caused by the presence of bone cells in the wells.
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results indicated that the presence of bone cells at the bot-
tom of the inserts was required for AM-1 cell migration. 
However, in both cases only a small number of cells 
migrated, which is consistent with the slow invasion of 
AM tumour cells in vivo.22
To further examine the behaviour of AM cells in the 
scaffolds and assess the interactions between the tumour 
and the bone cells, gene expression analysis was carried 
out on selected genes, which have previously been found 
to be important in AM bone turnover regulation in tumours.
RANKL and OPG are, as discussed above, integral to 
bone turnover regulation in both healthy and diseased 
bones. Previous studies have shown variable levels of the 
protein products of these genes in a variety of AM 
tumours.10,23 These genes were chosen as examples in 
order to probe the organotypic environment in which the 
AM cells are seeded in and proliferated in.
An approximately 700-fold increase in RANKL expres-
sion in the AM co-culture models was seen (Figure 5(a)) 
when compared with single-cell-type cultures. This increase 
was seen in both the bone part of the model, with a gradual 
increase in the interface part of the two different gels. The 
level of RANKL in the AM-1 part of the co-culture 
construct was constant throughout the first 11 days of cul-
ture, rising significantly to around a 600-fold increase by 
2 weeks of culture (p < 0.05). This indicates that the presence 
of bone cells in the co-culture model caused AM-1 cells to 
increase RANKL to potentially upregulate bone resorption 
and to enable the tumour to further grow into the bone-like 
tissue. However, this model would further benefit from a 
co-culture with a non-cancerous bone cell line, as this unex-
pectedly large increase in RANKL levels may have been 
caused by the cancerous properties of the HOS cells in the 
co-cultures.
OPG gene expression levels remained approximately 
constant throughout the culture time (Figure 5(b)). By day 
14, however, there is a significant downregulation of OPG 
in the bone part of the model (p < 0.05). This downregula-
tion of OPG would further increase the rate of bone resorp-
tion in an in vivo tumour; as discussed before, OPG is a 
decoy RANKL receptor and an increase in OPG reduces 
bone resorption. OPG expression in AM tumours and 
RANKL expression have been detected in all ex vivo 
tumours examined.12,23 RANKL has been shown upregu-
lated in OSCC, and OPG expression has also been shown 
dysregulated in OSCC.9,24
As NF-κB is a downstream factor of RANKL, the gene 
expression of NF-κB was also examined. NF-κB levels in 
the models remained constant for the first 10 days in cul-
ture (Figure 5(c)). By day 14, there was a significant 
downregulation of NF-κB seen in the bone part of the co-
culture model (p < 0.05). This was due to the presence of 
AM-1 cells in the co-culture, as no such increase was seen 
in the bone-only controls. Immunohistochemical analysis 
into NF-κB in AM tumours has shown a lower expression 
of this gene in ex vivo tumours.12,25
Figure 5. Gene expression of the bone regulating genes 
RANKL, OPG and NF-κB in co-culture models. (a) Gene 
expression of RANKL increased significantly over the culture 
time in the bone part of the co-culture models. There was 
also an increase in the interface part of the models, whereas 
the levels stay relatively constant in both the AM-1 part of 
the models as well as the bone-like construct alone. (b) OPG 
expression in the co-culture models did not vary significantly 
for the first 10 days in culture. However, there is a significant 
downregulation of OPG in the bone part of the co-culture 
scaffolds by day 14 of co-culture. (c) NF-κB expression is 
slightly upregulated in the bone part of the scaffolds and 
downregulated in the AM-1 part of the scaffolds for the first 
10 days in co-culture. However, by day 14, there is a significant 
downregulation of NF-κB also in the bone part of the scaffolds. 
As no such change is seen in the bone-only control, this change 
is due to the presence of AM-1 cells in the model. HOS ctrl 
– HOS cells only in a single-cell-type culture gel. IF – interface 
region between the bone and AM-1 parts of the co-culture 
gels. Two-way ANOVA comparing the co-cultures to the 
corresponding parts of the single-cell culture constructs. 
***p < 0.001; ****p < 0.0001; (a, b) N = 6; (c) N = 3.
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Protein patched homolog 1 (PTCH1), which is a mem-
ber of the sonic hedgehog (SHH) pathway and is often 
implicated in AM tumours, increased steadily throughout 
the culture time in all parts of the construct, but were not 
found statistically significant when compared to controls 
(data not shown).
Further work to improve the model includes using oste-
oblasts from a non-cancerous cell line to improve the co-
culture models and to validate results shown here. A further 
study, such as that by Sandra et al.,26 using an osteoclast 
model, could be carried out to assess whether this change 
in gene expression translates to an increase in the bone-
invading capacity of the tumour cells.
Additionally, it would be interesting to incorporate AM 
cells from other cells lines or ex vivo tumours in the model 
to assess their growth and invasion in this organotypic 
environment. Recent studies have indicated BRAF V600E 
and other epidermal growth factor receptor (EGFR) path-
way genes5,27 – these would be interesting to investigate in 
our model to further characterise these tumours. This way, 
therapeutic compounds could also be tested and tailored to 
patient needs prior to clinical use.
Conclusion
We describe a process by which we have developed an in 
vitro cellularised, organotypic model of AM. Collagen, as 
used as the basis for this model, is an abundant extracel-
lular matrix protein throughout the body, including bone, 
and has previously been used for similar bone scaffolds.28 
This bone-like model enables close characterisation of the 
AM tumour pathogenesis, growth and gene expression, as 
presented here. AM cells in the scaffolds provided an 
organotypic model for the tumour in an in vitro setting and 
exhibited characteristics typical of this tumour.
The results shown here provide indications towards the 
bone absorption mechanism of AM as we have shown a 
large increase in the osteoclast-activating gene RANKL in 
the AM co-cultures, both in the HOS part of the co- 
cultures and the AM-1 part. This was due to the presence 
of HOS cells in the co-cultures, which appeared to increase 
RANKL expression in AM-1 cells, but further studies are 
needed to pin-point a specific mechanism. Additionally, 
this model was used for analysing the levels of other genes 
in the co-cultures, which have been implicated either in 
AMs or in other similar tumours.
This model can also be used as a supplementary method 
for high-throughput screening of potential therapeutic 
agents prior to clinical studies, and the model could pave 
way for further treatments as it can easily be adapted for 
screening of various therapeutic compounds. The cells in 
the model are in a tissue-like state and the therapeutic 
agents used would, therefore, have a tissue-like effect on 
the cells.
Furthermore, AM behaviour with other cells in the sur-
rounding native environment, such as fibroblasts, could be 
studied, as well as the tumours’ invasive behaviour towards 
these cells and tissues. This model can also be easily 
adapted for use with other oral tumours, such as OSCC, to 
provide an organotypic growth environment and easy 
examination of these tumours.
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